Antiviral Drugs Market by Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), Type (Branded and Generic), Application (HIV, Hepatitis, Influenza, Herpes, Others) and Region - Global Forecasts 2017 to 2027

Antiviral Drugs Market Report Overview

The global antiviral drugs market is projected to grow at a CAGR of 3.8% to reach USD $50 billion by 2027 from $39 billion in 2020. Rising awareness about viral infections, availability of diagnostics, presence of several drugs, and significant strategic initiatives by industry players has contributed to the growth of this market.

antiviral drugs market

The research report categorizes the antiviral drugs market to forecasts the revenues and analyses the trends in each of the following below mentioned market segments.

By Mechanism of Action

  • Nucleotide Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

Antiviral Drugs Market By Type:

  • Branded
  • Generic

By Application

  • HIV
  • Hepatitis
  • Influenza
  • Herpes
  • Others

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • New Zealand
    • Rest Of Asia Pacific
  • South America
  • ROW

The report also provides in-depth value chain analysis, opportunity mapping, technology landscape, regulatory scenario, patent trends, market trends, Covid-19 impact analysis, raw material supply analysis, pricing trends, sustainability trends and competitive landscape.

Antiviral Drugs Market Dynamics

Drivers: Rising viral infections and thereby growing demand of the drugs

Recent outbreaks of various viral infections such as Lassa virus, rare Nipah virus, and Corona virus is responsible for the high demand of antiviral drugs across the globe. Investment by market players in research and development activities is increasing significantly due to presence of high opportunities. This will further lead to entry of new drugs in the market and is anticipated to propel the market growth.    

Rising prevalence of HIV across the globe and enhanced surveillance rate are anticipated to fuel the market growth. For instance, according to WHO, about 37.9 million people were suffering from HIV across the world. Additionally, entry of blockbuster drugs such as, Biktarvy and Triumeq by Gilead Science and GlaxoSmithKline simultaneously, have changed the antiviral drugs market scenario.

The presence of rich product pipeline for various viral infections is anticipated to fuel the market growth. For instance, in March 2021, Pfizer initiated early-stage clinical trial of oral antiviral drug, PF-07321332 (Protease inhibitor), for coronavirus in the U.S. In August 2020, the European Commission approved Hepcludex, a first drug for hepatitis D in Europe. After several years of research, researchers got success to treat hepatitis D.  

Restraints: Stringent government regulations

Stringent government regulations associated with the approval and marketing of antiviral drugs across the globe further delay the drugs to enter in the market. The entire process is time consuming and costly which affects the cost of the drugs in the market. Hence, this may restrain the market growth. Additionally, presence of ayurvedic and homeopathic products to treat viral infection is anticipated to hamper the market growth.

Opportunity: Large patient pool of Corona virus and limited availability of vaccine and drugs 

Presence of large patient pool and limited availability of vaccines and drugs create several opportunities for new entrants in the market. Furthermore, the disease spread rapidly in many countries, hence the government is allowing faster approval of drugs and vaccines for Corona.

Challenges: High cost of drugs and virus variations

The antiviral drugs market is being impacted by the high cost of the drugs. Furthermore, virus changes its structure many times and hence chances of failure is also high. These are some of the major challenges of the market.

In terms of mechanism of action, protease inhibitor segment in the market is expected to be the largest segment during the forecast period

In terms of application, the global antiviral market has been segmented into Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others. In 2020, protease inhibitor segment accounted for the largest share of the market. Whereas, nucleotide polymerase inhibitor is expected to grow at the fastest rate during the forecast period.

By application, HIV is expected to be the largest segment

Based on application, the antiviral drugs market has been segmented into HIV, Hepatitis, Influenza, Herpes, and Others. In 2020, HIV held the largest segment of the market. This can be attributed to high prevalence of HIV, improved treatment regimen and patient adherence to treatment, and favourable reimbursement policies by the several governments of different countries.

Furthermore, participation of government in several countries to increase awareness about virology, investment by market players to develop effective drugs to treat HIV, and development of comprehensive guidelines for the HIV treatment is expected to maintain its dominance during the forecast period.

Asia-Pacific is expected to register the highest CAGR while North America is expected to be the largest Antiviral Drugs Market during the forecast period

Local presence of industry players, high purchasing power, availability of diagnostics, and favourable insurance policies are responsible for contributing the largest share of the market. Moreover, the presence of large aging population and recent approvals by the U.S. FDA are expected to further propel the demand for antiviral drugs in the region.

Rich clinical pipeline in the region due to availability of government funding and high investment by market players in research and development activities are anticipated to observe significant growth during the forecast period in the region. The U.S. contributed maximum share in the region.

The Asia-Pacific region is projected to be the fastest-growing market due to presence of large patient pool, increasing awareness about viral infections, rising diagnosis rate, and growing middle class in the region. Furthermore, increasing investment in research and development activities and availability of several antiviral drugs further propel the antiviral drugs market in the region. China, India, Japan, and Singapore are major contributing countries in the Asia Pacific region.

Company Profiles and Competitive Intelligence covered in Antiviral Drugs Market Report:

The market is highly fragmented with presence of international and regional players. The key players operating in the market are

  1. F. Hoffmann-La Roche Ltd.
  2. GlaxoSmithKline
  3. Abbott Laboratories
  4. Bristol-Myers-Squibb
  5. Gilead Sciences
  6. AstraZeneca plc.
  7. Schering-Plough Corporation
  8. AbbVie Inc.
  9. Johnson & Johnson
  10. Merck & Co., Inc.
  11. Pfizer Inc.
  12. Sun Pharmaceuticals
  13. Teva Pharmaceutical Industries Ltd.
  14. Boehringer Ingelheim International GmbH
  15. Dynavax Technologies Corporation
  16. Vertex Pharmaceuticals Incorporated
  17. Achillion Pharmaceuticals

Innovative product development, collaborations and partnerships for development or marketing, and geographical expansions through acquisitions and mergers are some of the strategies adopted by market players to enhance their presence in the industry.

Recent Developments in Antiviral Drugs Industry

  • In October 2020, Roche signed a collaboration agreement with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
  • In October 2020, Novartis collaborated with Molecular Partners, a global leader in the development of DARPin® therapeutics, to develop two DARPin® therapies for COVID-19 patients
  • In October 2020, the U.S.FDA approved first treatment, remdesivir, to treat hospitalized COVID-19 patients
  • In March 2020, Iktos collaborated with SRI International to Combine novel automated discovery platform and artificial intelligence for accelerated development of new anti-viral therapies.
  • In July 2020, Remdesivir received a one-year conditional marketing authorization from the European Commission due to the urgency of the Covid-19 pandemic. Hence, such an accelerated approval of drugs is anticipated to boost the market growth.
  • In February 2018, Vaxart, Inc. merged with Aviragen Therapeutics, Inc. According to Vaxart, this merger will allow access to direct acting antivirals and pipeline of oral vaccines, developed by Aviragen Therapeutics, Inc.

Frequently Asked Questions (FAQs)

The antiviral drugs market was estimated at 39 USD billion in 2020

The antiviral drugs market is estimated to grow at a CAGR of 3.8%

HIV was estimated to be the largest market segment of the antiviral drugs market in 2020

F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Abbott Laboratories, Bristol-Myers-Squibb, Gilead Sciences, AstraZeneca plc., Schering-Plough Corporation, AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., Pfizer Inc

The report analyses the impact of Covid-19 on the antiviral drugs market in detail. With increase in patient population, Covid19 impacted positively on the market.

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports


    1. Product Outline
    2. What are Antiviral Drugs?
    3. What are different types of Antiviral Drugs
    4. Market Snapshot
    5. Analysis of Antiviral Drugs: Value Chain
    6. Supply Chain Analysis
    7. Covid -19 Impact
    8. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
  2. Antiviral Drugs Market by Mechanism of Action
    1. Nucleotide Polymerase Inhibitors
    2. Reverse Transcriptase Inhibitors
    3. Protease Inhibitors
    4. Others
  3. Antiviral Drugs Market by Type
    1. Branded
    2. Generic
  4. Antiviral Drugs Market by Application
    1. HIV
    2. Hepatitis
    3. Influenza
    4. Herpes
    5. Others
  5. Regulatory Landscape and Clinical Trial Analysis for Antiviral Drugs
    1. Approval Procedure by Region
    2. Clinical Trial Analysis
  6. Regional Analysis
    1. North America
      1. US
      2. Canada
      3. Mexico
    2. Europe
      1. Germany
      2. UK
      3. France
      4. Italy
      5. Spain
      6. Netherlands
      7. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. New Zealand
      6. Rest Of Asia Pacific
    4. Middle East and Africa
    5. South America
  7. New Opportunities and Unmet Needs
    1. Opportunity mapping
    2. Supply and Demand Analysis
    3. Key Market Trends
  8. Competitive Scenario
    1. Competitive Strategies of Key Players
      1. Mergers and Acquisitions
      2. Investments
      3. Joint Ventures
      4. New Product launches
    2. Strength of product portfolio
    3. Ranking of Key Players
    4. List of Major Players by Geographies

    1. F. Hoffmann-La Roche Ltd.
    2. GlaxoSmithKline
    3. Abbott Laboratories
    4. Bristol-Myers-Squibb
    5. Gilead Sciences
    6. AstraZeneca plc.
    7. Schering-Plough Corporation
    8. AbbVie Inc.
    9. Johnson & Johnson
    10. Merck & Co., Inc.
    11. Pfizer Inc.

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization